Article
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine - 1 Mar 2017
Chang Huang-Chih, Chen Yu-Mu, Tseng Chia-Cheng, Huang Kuo-Tung, Wang Chin-Chou, Chen Yung-Che, Lai Chien-Hao, Fang Wen-Feng, Kao Hsu-Ching, Lin Meng-Chih
Abstract excerpt
Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are first-choice treatments for advanced non-small-cell lung cancer patients harboring EGFR mutations. Although EGFR mutations are strongly predictive of patients' outcomes and their response to treatment with EGFR-TKIs, early failure of first-line therapy with EGFR-TKIs in patients with EGFR mutations is not rare. Besides several clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.